Media RelationsAmy Rose-1 (212) 733-7410Amy.Rose@pfizer.com In September, companies concluded exploratory talks with the EC on the provision of doses of the vaccine candidate, if approved, and the final delivery agreement is now final. Under the agreement, Pfizer will pay $185 million U.S. to BioNTech in advances, including a cash payment of $72 million and a $113 million stake. BioNTech is entitled to future milestone payments of up to $563 million for a potential $748 million. Pfizer and BioNTech share development costs equally. Initially, Pfizer will finance 100% of the development costs and BioNTech will reimburse Pfizer for its 50% share of these costs during the commercialization of the vaccine. NEW YORK – MAINZ, Germany— (BUSINESS WIRE)– Pfizer (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that they have agreed with the European Commission to provide European Union (EU) Member States with 200 million doses of SARS-CoV-2 vaccines, based on ARSE BNT162b2. Deliveries are expected to begin at the end of 2020, subject to clinical success and administrative approval. Vaccine doses for Europe are produced at BioNTech`s German production sites and at Pfizer`s production site in Belgium. If the vaccine candidate BNT162b2 is approved by the European Medicines Agency (EMA), the doses are ordered by the EU Member States who have opted for the vaccine under this agreement. ”The expansion of Operation Warp Speed`s diversified portfolio by adding a vaccine between Pfizer and BioNTech increases the likelihood that we will have a safe and effective vaccine by the end of this year,” said Alex Azar, Secretary of HHS.
”Depending on the success of clinical trials, today`s agreement will deliver approximately 100 million doses of this vaccine to the American people.” As part of the agreement, Pfizer and BioNTech will supply BNT162b2 to the Member States of the European Union (EU). ”Today`s delivery agreement with the European Commission is the first order for vaccine doses for Pfizer and BioNTech and is an important step towards our common goal of making a Covid 19 vaccine available to vulnerable populations.” BioNTech Forward-Looking StatementsThe press release contains ”forward-looking statements” from BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may contain information about BioNTech`s efforts to combat COVID-19, but not limited to this: the opening date of clinical trials with BNT162 and the likely publication of data from these clinical trials; The date of authorization or authorization for the use of an emergency physician; The potential for additional supply agreements with other legal systems or the COVAX facility; the potential to provide the U.S. with additional doses of our vaccine as part of the U.S. government`s option to purchase additional doses; The potential safety and effectiveness of BNT162; BioNTech and Pfizer`s cooperation in developing a potential COVID-19 vaccine; and BioNTech`s ability to provide quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. All forward-looking statements contained in this press release are based on BioNTech`s current expectations and beliefs in future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and negatively from the results presented or implied in such forward-looking statements.